Sign Up to like & get
recommendations!
1
Published in 2022 at "ESC Heart Failure"
DOI: 10.1002/ehf2.13963
Abstract: Duchenne muscular dystrophy (DMD) is an X‐linked recessive neuromuscular disorder, characterized by significant long‐term cardiac involvement. Dilated cardiomyopathy (DCM) is the main cause of death in DMD, and angiotensin‐converting enzyme inhibitors (ACEi) and beta‐blockers (BB)…
read more here.
Keywords:
angiotensin;
neprilysin inhibitor;
receptor neprilysin;
angiotensin receptor ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "International journal of cardiology"
DOI: 10.1016/j.ijcard.2016.06.083
Abstract: Sacubritil∗valsartan (Entresto, Novartis, still commonly referred to as LCZ696) is a combination drug described as a new class of dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). This combination drug has been successfully studied in patients with heart…
read more here.
Keywords:
new class;
angiotensin receptor;
receptor neprilysin;
neprilysin inhibitor ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2019 at "European Heart Journal"
DOI: 10.1093/eurheartj/ehz746.0392
Abstract: Angiotensin receptor-neprilysin inhibitor (ARNI) increases natriuretic peptide and improves heart failure. We previously reported that ARNI has the effects of suppression of myocardial hypertrophy and fibrosis in addition to reduction of afterload by natriuretic effect.…
read more here.
Keywords:
arni;
neprilysin inhibitor;
group;
ctl group ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Hospital Pharmacy"
DOI: 10.1177/0018578720946756
Abstract: Purpose: Angiotensin receptor-neprilysin inhibitor (ARNI) therapy has been reported to be initiated in patients on vasoactive medications during acute decompensated heart failure. However, there is...
read more here.
Keywords:
angiotensin receptor;
receptor neprilysin;
neprilysin inhibitor;
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2022.899235
Abstract: Cardiovascular disease (CVD) has become a huge challenge for the global public health system due to its high morbidity, mortality and severe economic burden. In recent years, angiotensin receptor neprilysin inhibitor (ARNI), a new class…
read more here.
Keywords:
receptor neprilysin;
medicine;
angiotensin receptor;
neprilysin inhibitor ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Frontiers in Medicine"
DOI: 10.3389/fmed.2022.877237
Abstract: Chronic kidney disease (CKD) is a global public health problem, and cardiovascular disease is the most common cause of death in patients with CKD. The incidence and prevalence of cardiovascular events during the early stages…
read more here.
Keywords:
disease;
angiotensin;
angiotensin receptor;
neprilysin inhibitor ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Cardiology journal"
DOI: 10.5603/cj.a2018.0048
Abstract: BACKGROUND Recent clinical studies have shown that treatment with LCZ696, a complex containing the angiotensin receptor blocker valsartan and neprilysin inhibitor sacubitril, improves the prognosis of heart failure patients with a reduced ejection fraction. This…
read more here.
Keywords:
fibrosis;
iso;
angiotensin receptor;
neprilysin inhibitor ... See more keywords